BioSpace News Archive

Aphios Corporation today announced that it has been granted Chinese Patent No. 201811111996.8 by China National Intellectual Property Administration on October 26, 2021.

X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, announced that management will participate in a fireside chat at Stifel’s Virtual Healthcare Conference on Wednesday, November 17, 2021.

Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), today announced that it will host a key opinion leader (KOL) webinar on the role iNKT cells play in anticancer immune response and how iNKT targeting can be leveraged to expand the immuno-oncology landscape, Thursday, November 18, 2021, at 10a.m. Eastern Time.

Eiger BioPharmaceuticals, Inc. today announced that David Cor , President and CEO, will provide a corporate update at two investor conference events in November:

THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, announced the appointment of David C. Dvorak as the Executive Chairman of its Board of Directors.

Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine

Savara Inc. today announced that its management team will present at the Jefferies London Healthcare Conference being held November 16-19, 2021.

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results before the market opens on Monday, November 15, 2021 .

Medexus Pharmaceuticals Inc. today announced its financial results and provided a business update for the three-month period ended September 30, 2021.

Under the terms of the agreement, worth up to €8.7 million, Hyloris will provide €1 million in several tranches over time, automatically convertible into Pleco equity under certain conditions, together with potential funding of up to an additional €7.7 million in pre-defined R&D activities against an agreed development plan.